Decorative image

Sudden Cardiac Arrest

Clinical Studies and Outcomes

Medtronic offers a full line of defibrillation devices and services for physicians treating patients at risk of sudden cardiac arrest.

Expand All

MADIT

Multicenter Automatic Defibrillator Implantation Trial (MADIT)

An overview of the MADIT1-3 trial is included below.

Primary Prevention Trial – Implantable Cardioverter Defibrillator (ICD) vs. Antiarrhythmic Drug Treatment in Post-MI Patients

Protocol

MADIT Trial – Protocol

Hypothesis

To study whether, in patients with a previous MI and LV dysfunction, prophylactic therapy with an ICD can improve survival versus treatment with conventional medical therapy (eg, amiodarone, beta-blockers/sotalol and class I antiarrhythmics).

Primary Endpoint

  • Total mortality

Secondary Endpoints

  • Arrhythmic mortality
  • Costs and cost effectiveness

Results

In post-MI patients at a high risk for VT, prophylactic therapy with an ICD reduced overall mortality by 54% and arrhythmic mortality by 75% compared with conventional medical therapy after a mean follow-up of 27 months.


References

1

Moss AJ. Multicenter Automatic Defibrillator Implantation Trial (MADIT): design and clinical protocol. PACE, 1991;14:920-927.

2

Moss AJ, Jackson Hall W, Cannom DS, et al., for the MADIT investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933-1940.

3

Mushlin A, Jackson Hall W, Zwanziger J, et al., for the MADIT investigators. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Circulation. 1998;97:2129-2135.

MUSTT

MADIT II

SCD-HeFT

AVID

CIDS

CASH